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A B S T R A CT  
Background  
Neurological features of COVID-19 have been reported in addition to the respiratory manifestations, 
but cognitive dysfunction has been scarcely described. And cognitive assessment has not been studied 
in asymptomatic subjects. 
Method 
We compared the cognitive assessment scores between asymptomatic SARS-CoV-2 infected subjects 
with that of controls to detect mild cognitive impairment by the Montreal Cognitive Assessment test. 
Result 
Asymptomatic COVID-19 subjects secured lower scores in certain domains of the MoCA in 
comparison with the controls. The domains were visuoperception 
(2.4±0.7 vs2.8±0.7, p=0.032), naming (3.6±0.5 vs3.9±0.2, p=0.016) and fluency (0.9±0.6 vs1.6±0.7, 
p=<0.001). Also, older aged COVID-19 positive subjects scored lower in the MoCA when compared 
to the younger people. 
Conclusion 
Our study shows that even otherwise asymptomatic COVID-19 subjects have cognitive deficits in 
certain subdomains and suggests the need for a detailed psychometric assessment especially in the 
elderly population. 
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1 Introduction 
COVID-19, caused by SARS-CoV-2 has killed millions of people across the world in less than a year. It has 
affected almost all of the human population directly or indirectly. Directly by causing a spectrum of 
disorders ranging from no symptoms to death. Indirectly by resulting in sickness or loss of a family member 
or socioeconomic turbulence due to restricted movement of parcels and people [1]. The people afflicted 
with SARS-CoV-2 were reported to have respiratory symptoms in the earliest studies. Thereafter a number 
of extra respiratory features were also observed. These included neurological deficits also. Some of these 
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were stroke, seizures, neuropathy and movement disorders [2]. Recent pathological studies have shown the 
neurotropism of SARS-CoV-2, thus establishing a direct pathophysiological basis to the neurological 
features [3]. 
Neurological features of higher mental functions were reported by Zhou et al who performed a study on 
the cognitive functions of 29 COVID-19 recovered patients. The patients secured lower scores in 
Continuous Performance Test (which is used to assess attention and impulse) than the controls [4]. Others 
have reported a dysexecutive syndrome in the COVID-19 patients [5]. Thus, symptomatic patients do suffer 
cognitive deficits in addition to the earlier reported neurological features. Neurological features such as 
weakness, pain and numbness are reported readily as they are easily noticed by the patients. However, 
dysfunctions of the higher mentation go unnoticed especially if they are mild and occur in otherwise 
asymptomatic persons [6]. Such unrecognised deficits have been brought out in asymptomatic subjects in 
many other diseases by targeted cognitive tests like MiniMental Status Examination (MMSE) and Montreal 
Cognitive Assessment (MoCA) [7,8]. Although MMSE has been widely used for detecting cognitive 
impairment, it has been found inferior [9] to the MoCA in detecting Mild cognitive impairment (MCI). 
MoCA has been widely validated in diagnosing MCI in many studies [6]. We used the MoCA test to detect 
MCI in asymptomatic COVID-19 subjects. 
2 Methods 
As a case control study at the department of General Medicine, Great Eastern medical School and Hospital, 
Ragole, India we compared the cognitive assessment scores of 93 asymptomatic COVID-19 subjects with 
those of 102 controls. The study was conducted from June 2020 to July 2020. Laboratory-confirmation of 
SARS-CoV-2 infection was done by RT-PCR on nasopharyngeal swabs. The subjects were recruited from 
relatives of COVID-19 patients brought to the hospital. Control subjects were negative for the infection. 
All subjects with age <18 years, comorbidities, psychiatric illness or if on any medication were excluded. 
The sample size was calculated to 91 cases and 91 controls based on the previous study by Zhou et al. We 
recruited 105 subjects in each group. The subjects were then administered the MoCA basic test in the local 
language as all of them had less than four years of education. MoCA includes nine domains: executive 
function, fluency, orientation, calculation, abstraction, delayed recall, visuoperception, naming and 
attention.  Cognitive impairment is defined as score less than or equal to 26 out of 30. The scores were 
compared between cases and controls. Permission was obtained to use the MoCA for the study. The data 
was analyzed using IBM SPSS Statistics-version 21 (IBM Corp. Released 2012. IBM SPSS Statistics for 
Windows, Version 21.0. Armonk, NY: IBM Corp.). The data is presented as mean and standard deviation. 
Tests of significance used were t-test, one-way ANOVA for parametric data. The data is available with the 
corresponding author.  
3 Results 
In our study we finalised 93 asymptomatic COVID-19 patients and 102 controls after exclusion due to lack 
of consent and insufficient data. The mean age of the patients was 36.2±11.7 and that of the controls was 
35.6±9.8. In the COVID-19 subjects 52.3% were women and in the controls 54.7% were women. 
There was no significant difference in the overall cognitive assessment scores between the two groups, but 
COVID-19 patients secured lower scores than controls in the domains of visuoperception, naming and 
fluency. (Table 1) 
Also, COVID-19 positive subjects aged greater than 50 years scored lower in the MoCA when compared 
to the younger people. (Table 2). There were no differences between the two genders (Supplementary table). 
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Table 1: Montreal Cognitive Assessment scores of the subjects 
Domain (Max. score) Asymptomatic 
COVID-19 
subjects (93) 
Controls (102) p value 95%CI 
Mean Total Score (30) 26±2.6 26.1±3.0 0.887 -1.492 to 1.292 
Executive function (1) 0.9±0.2 0.9±0.2 1 -0.105 to 0.105 
Fluency (2) 0.9±0.6 1.6±0.7 <0.001 -1.002 to -0.378 
Orientation (6) 5.6±0.6 5.6±1 1 -0.353 to 0.353 
Calculation (3) 2.4±0.8 2.4±0.9 1 -0.426 to 0.426 
Abstraction (3) 2.8±0.5 2.6±1 0.209 -0.114 to 0.514 
Delayed recall (5) 3.1±1.1 3.2±1 0.728 -0.668 to 0.468 
Visuoperception (3) 2.4±0.7 2.8±0.7 0.032 -0.766 to -0.034 
Naming (4) 3.6±0.5 3.9±0.2 0.016 -0.545 to -0.055 
Attention (3) 2.5±0.5 2.6±0.8 0.496 -0.390 to 0.190 
Table 2: Age wise comparison of the MoCA scores. 
 Age 18 - 29 30 - 49 50 and above P value  
Mean MoCA Score 
in Cases 
25.9±2.1 25.9±2.3 24±3.5 0.018 
Mean MoCA Score 
in Controls 
27±1.7 25.6±4.3 24.5±3.5 0.537 
Number of Cases =33 (Age 18 – 29) vs 42 (30-49) vs 18 (50 and above). Number of Controls 48 vs 42 vs 12. 
Cases 
Tukey HSD Post-hoc Test... 
Age 18 - 29 vs Age 30 - 49: Diff=0.0000, 95%CI=-1.3905 to 1.3905, p=NaN 
Age 18 - 29 vs Age 50 and above: Diff=-1.9000, 95%CI=-3.6515 to -0.1485, p=0.0302 
Age 30 - 49 vs 50: Diff=-1.9000, 95%CI=-3.5840 to -0.2160, p=0.0230 
Controls 
Tukey HSD Post-hoc Test... 
Age 18 - 29 vs Age 30 - 49: Diff=-1.4000, 95%CI=-5.7355 to 2.9355, p=0.6821 
Age 18 - 29 vs Age 50 and above: Diff=-2.5000, 95%CI=-9.1226 to 4.1226, p=0.5961 
Age 30 - 49 vs Age 50 and above: Diff=-1.1000, 95%CI=-7.8166 to 5.6166, p=0.9044 
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4 Discussion 
We found that asymptomatic COVID-19 patients had impairments in certain cognitive domains. They 
included visuoperception, naming and fluency. Older patients had more MCI compared to the subjects 
below 50 years of age. Our study adds to the Zhou et al study that showed defects of CPT in COVID-19 
patients and extends the neurological spectrum even to otherwise asymptomatic subjects. These findings 
confirm the cognitive impairments due to COVID-19. 
The dysfunction in multiple cognitive domains corresponds to dysfunction of multiple parts of the brain 
[10]. This is in line with previous neuropathological [11,12] and neuroimaging studies [13] which have 
shown that viral pathology involves most of the brain. These neurological patterns have been associated 
with most of the corona viruses [14]. Direct neural invasion, neuroinflammation and systemic 
proinflammatory state and hypoxia have all been suggested to mediate the neurological dysfunction in 
COVID-19 [15]. An interesting study has shown that asymptomatic subjects also may have pneumonia 
discernible only by imaging [16]. It may even be possible that the MCI in our COVID-19 subjects might 
be due to impaired oxygen supply to the brain [15], keeping in mind that even hypoxia goes undetected in 
some patients even with a pulse oximeter [17]. 
Our finding of cognitive impairment in asymptomatic COVID-19 patients is important especially in elderly 
patients if they already have MCI. It might be further compromised. Even without other symptoms they 
might thus need more vigilant care [18] as their activities of daily living [ADL] might be affected.  
From our findings, it may be suggested that people employed in highly intellectual occupations might fall 
short of their work requirements if they have COVID-19 infection even asymptomatically. This is pertinent 
as doctors and medical personnel who are at a very high risk for the infection come under this category and 
their mental health condition is paramount to every medical strategy against COVID-19.  
Previous literature has hypothesized that COVID-19 affected patients might be at high risk of developing 
cognitive decline after overcoming the primary infection [19]. The cognitive impairment reported in our 
study and the previous studies [4,5] suggests the need for long term follow up of the COVID-19 affected 
subjects as people with MCI are prone to dementia [20].  
5 Conclusion 
Our study shows that even otherwise asymptomatic COVID-19 subjects have cognitive deficits in certain 
subdomains and suggests the need for a detailed psychometric assessment especially in the elderly 
population. 
6 Declarations 
6.1 Study Limitations 
Our study is limited by the small sample and the hospital bias but it suggests MCI in asymptomatic COVID-
19 subjects. And since only one test was done, a full psychometric assessment study is warranted to fully 
understand the pattern better. 
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7 Supplementary Table 
Gender wise MoCA score comparison 
Cases 49m vs 51f.  Controls 44m vs 56f 
 Males Females P value 95%CI 
Mean MoCA 
Score in Cases 
25.4±2.7 25.8±2.5 0.49 -0.762 to 1.562 
Mean MoCA 
Score in Controls 
27.2±2.6 25.5±3.4 0.31 -5.114 to 1.714 
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